Morgan Stanley analyst Craig Hettenbach initiated coverage of Hinge Health (HNGE) with an Overweight rating and $46 price target Hinge is a category leader in virtual musculoskeletal care with a “highly scalable, differentiated AI-driven platform,” the analyst tells investors in a research note. The firm says that in contrast to many digital health companies that benefitted from a material uptick in spending during Covid only to see growth slow materially to single digits, Hinge saw an acceleration in year-over-year growth to 44% and 50% in the last two quarters, respectively. Morgan Stanley sees a “strong case for a higher multiple as margins expand.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE: